查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585693

膀胱癌藥物市場：按治療類型、膀胱癌類型和最終用戶分類 - 全球預測 2025-2030

Bladder Cancer Therapeutics Market by Treatment Type (Chemotherapy, Gene Therapy, Immunotherapy), Bladder Cancer Type (Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Superficial Bladder Cancer), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年膀胱癌治療市場價值為52.1億美元，預計到2024年將達到55.6億美元，複合年成長率為7.23%，到2030年將達到84.9億美元。

膀胱癌藥物市場包括多種旨在控制和治癒膀胱癌（一種癌症）的治療方法。不同癌症階段的治療包括化療、免疫治療、放射線治療和標靶治療。這些治療方法的需求源於與膀胱癌相關的高復發率和顯著的患者發病率。這些治療方法適用於醫院、診所和專門的癌症治療中心。主要最終用戶包括醫療保健提供者、患者和研究人員，每個人都在尋求能夠帶來更好結果的進步。一個主要促進因素是膀胱癌盛行率不斷上升，刺激了對先進治療方法的需求。此外，意識的提高和政府促進早期診斷和早期治療的措施也有助於市場擴張。然而，高昂的治療成本、現有治療的副作用以及嚴格的監管要求等挑戰正在阻礙成長。新型療法的研究和開發存在商機，例如個人化醫療和標靶治療，它們有可能減少副作用並提高療效。新興市場也擴大採用先進的醫療保健解決方案，帶來了利潤豐厚的商機。為了抓住這些機遇，產業參與者應該投資研發並與研究機構合作推動創新。加強藥物分銷管道和提高對新治療方法的認知也至關重要。限制包括新藥核准過程漫長，以及與現有療法的競爭可能會延遲新療法的推廣。對於尋求發展的公司來說，擴展到生技藥品、基因治療和奈米技術是有前途的創新領域。市場競爭激烈，持續成長需要持續創新和策略聯盟。了解病患需求和監管環境對於相關人員駕馭這個複雜但機會豐富的市場至關重要。

主要市場統計
基準年[2023] 52.1億美元
預測年份 [2024] 55.6億美元
預測年份 [2030] 84.9億美元
複合年成長率（%） 7.23%

市場動態：揭示快速發展的膀胱癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變膀胱癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球膀胱癌發生率上升
    • 提高對膀胱癌的認知並及時治療
    • 加速開發針對癌症的新藥
  • 市場限制因素
    • 膀胱癌治療高成本
  • 市場機會
    • 將機器學習 (ML) 和人工智慧 (AI) 融入膀胱癌藥物中
    • 持續開發膀胱癌治療的標靶治療和個人化醫療
  • 市場挑戰
    • 執行複雜治療的熟練醫護人員有限

波特五力：開拓膀胱癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解膀胱癌治療市場的外部影響

外部宏觀環境因素在塑造膀胱癌治療藥物市場的績效動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解膀胱癌治療藥物市場的競爭狀況

膀胱癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣膀胱癌治療市場供應商的績效評估

FPNV定位矩陣是評估膀胱癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃膀胱癌治療市場的成功之路

膀胱癌治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球膀胱癌發生率增加
      • 提高對膀胱癌和適當治療的認知
      • 加大抗癌新藥的開發力道
    • 抑制因素
      • 膀胱癌治療費用高昂
    • 機會
      • 將機器學習 (ML) 和人工智慧 (AI) 融入膀胱癌藥物中
      • 持續開發膀胱癌治療的標靶治療和個人化醫療
    • 任務
      • 缺乏能夠進行複雜治療的熟練醫療保健專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的膀胱癌治療藥物市場

  • 化療
  • 基因治療
  • 免疫療法
  • 放射治療
  • 外科手術
  • 標靶治療

第7章依膀胱癌類型分類的膀胱癌治療藥物市場

  • 浸潤性膀胱癌
  • 膀胱鱗狀細胞癌
  • 表淺性膀胱癌
  • 膀胱移行細胞癌

第8章膀胱癌治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 癌症專科門診

第9章 北美和南美膀胱癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區膀胱癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲膀胱癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amneal Pharmaceuticals LLC
  • AroCell AB
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • Olympus Corporation
  • Pacific Edge Ltd.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • UroGen Pharma Ltd.
Product Code: MRR-521BAA36EA72

The Bladder Cancer Therapeutics Market was valued at USD 5.21 billion in 2023, expected to reach USD 5.56 billion in 2024, and is projected to grow at a CAGR of 7.23%, to USD 8.49 billion by 2030.

The bladder cancer therapeutics market encompasses a range of treatments aimed at managing and potentially curing bladder cancer, a prevalent and recurrent form of cancer. It includes therapies such as chemotherapy, immunotherapy, radiation, and targeted treatments that address various cancer stages. The necessity for these therapeutics arises from the high recurrence rate and significant patient morbidity associated with bladder cancer. These therapies find application in hospitals, clinics, and specialized cancer treatment centers. Key end-users include healthcare providers, patients, and researchers, each looking for advancements that promise better outcomes. A major growth driver is the increasing prevalence of bladder cancer, spurring demand for advanced treatments. Additionally, growing awareness and government initiatives promoting early diagnosis and treatment contribute to market expansion. However, challenges such as high treatment costs, side effects of existing therapies, and stringent regulatory requirements impede growth. Opportunities lie in research and development of novel therapeutics like personalized medicine and targeted therapies, which could potentially reduce side effects and enhance efficacy. Emerging markets are also showing increased adoption of advanced healthcare solutions, presenting lucrative opportunities. To capture these opportunities, industry players should invest in R&D and collaborate with research institutions to drive innovation. Enhancing drug distribution channels and creating awareness about newer therapies is also vital. Limitations include the slow drug approval process and competition from existing therapies that may delay the uptake of new treatments. For businesses aiming at growth, venturing into biologics, gene therapies, and nanotechnology offers promising innovation areas. The market is characterized by intense competition, requiring continuous innovation and strategic partnerships for sustained growth. Understanding patient needs and regulatory landscapes will be crucial for stakeholders navigating this complex yet opportunity-rich market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.21 billion
Estimated Year [2024] USD 5.56 billion
Forecast Year [2030] USD 8.49 billion
CAGR (%) 7.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bladder Cancer Therapeutics Market

The Bladder Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of bladder cancer across the world
    • Growing awareness about bladder cancer and timely treatment
    • Increasing development of new cancer-targeting drugs
  • Market Restraints
    • High cost associated with bladder cancer treatment
  • Market Opportunities
    • Incorporation of machine learning (ML) and artificial intelligence (AI) in bladder cancer therapeutics
    • Ongoing development of targeted therapies and personalized medicine for bladder cancer treatment
  • Market Challenges
    • Limited availability of skilled healthcare professionals for administering complex treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bladder Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bladder Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bladder Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bladder Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bladder Cancer Therapeutics Market

A detailed market share analysis in the Bladder Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bladder Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bladder Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bladder Cancer Therapeutics Market

A strategic analysis of the Bladder Cancer Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bladder Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amneal Pharmaceuticals LLC, AroCell AB, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Merck KGaA, Olympus Corporation, Pacific Edge Ltd., Pfizer Inc., Spectrum Pharmaceuticals, Inc., and UroGen Pharma Ltd..

Market Segmentation & Coverage

This research report categorizes the Bladder Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
  • Based on Bladder Cancer Type, market is studied across Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Superficial Bladder Cancer, and Transitional Cell Bladder Cancer.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Cancer Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of bladder cancer across the world
      • 5.1.1.2. Growing awareness about bladder cancer and timely treatment
      • 5.1.1.3. Increasing development of new cancer-targeting drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with bladder cancer treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Incorporation of machine learning (ML) and artificial intelligence (AI) in bladder cancer therapeutics
      • 5.1.3.2. Ongoing development of targeted therapies and personalized medicine for bladder cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled healthcare professionals for administering complex treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bladder Cancer Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Gene Therapy
  • 6.4. Immunotherapy
  • 6.5. Radiation therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Bladder Cancer Therapeutics Market, by Bladder Cancer Type

  • 7.1. Introduction
  • 7.2. Invasive Bladder Cancer
  • 7.3. Squamous Cell Bladder Cancer
  • 7.4. Superficial Bladder Cancer
  • 7.5. Transitional Cell Bladder Cancer

8. Bladder Cancer Therapeutics Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Cancer Clinics

9. Americas Bladder Cancer Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bladder Cancer Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bladder Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Amneal Pharmaceuticals LLC
  • 4. AroCell AB
  • 5. Bristol-Myers Squibb Company
  • 6. Eisai Co., Ltd.
  • 7. Eli Lilly and Company
  • 8. Endo International PLC
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Hikma Pharmaceuticals PLC
  • 12. Johnson & Johnson Services, Inc.
  • 13. Koninklijke Philips N.V.
  • 14. Merck KGaA
  • 15. Olympus Corporation
  • 16. Pacific Edge Ltd.
  • 17. Pfizer Inc.
  • 18. Spectrum Pharmaceuticals, Inc.
  • 19. UroGen Pharma Ltd.

LIST OF FIGURES

  • FIGURE 1. BLADDER CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLADDER CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLADDER CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLADDER CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLADDER CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLADDER CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INVASIVE BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SUPERFICIAL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TRANSITIONAL CELL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. BLADDER CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. BLADDER CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023